In vitro activity of nemonoxacin, a novel nonfluorinated quinolone antibiotic, against Chlamydia trachomatis and Chlamydia pneumoniae
- PMID: 24366753
- PMCID: PMC3957896
- DOI: 10.1128/AAC.02263-13
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone antibiotic, against Chlamydia trachomatis and Chlamydia pneumoniae
Abstract
The in vitro activities of nemonoxacin, levofloxacin, azithromycin, and doxycycline were tested against 10 isolates each of Chlamydia trachomatis and Chlamydia pneumoniae. The MICs at which 90% of the isolates of both C. trachomatis and C. pneumoniae were inhibited (MIC90s) were 0.06 μg/ml (range, 0.03 to 0.13 μg/ml). The minimal bactericidal concentrations at which 90% of the isolates were killed by nemonoxacin (MBC90s) were 0.06 μg/ml for C. trachomatis (range, 0.03 to 0.125 μg/ml) and 0.25 for C. pneumoniae (range, 0.015 to 0.5 μg/ml).
Similar articles
-
In vitro activity of AZD0914, a novel DNA gyrase inhibitor, against Chlamydia trachomatis and Chlamydia pneumoniae.Antimicrob Agents Chemother. 2014 Dec;58(12):7595-6. doi: 10.1128/AAC.03920-14. Epub 2014 Oct 6. Antimicrob Agents Chemother. 2014. PMID: 25288086 Free PMC article.
-
In vitro activities of BMS-284756 against Chlamydia trachomatis and recent clinical isolates of Chlamydia pneumoniae.Antimicrob Agents Chemother. 2002 Feb;46(2):517-8. doi: 10.1128/AAC.46.2.517-518.2002. Antimicrob Agents Chemother. 2002. PMID: 11796366 Free PMC article.
-
In vitro activity of CEM-101, a new fluoroketolide antibiotic, against Chlamydia trachomatis and Chlamydia (Chlamydophila) pneumoniae.Antimicrob Agents Chemother. 2010 Mar;54(3):1358-9. doi: 10.1128/AAC.01343-09. Epub 2009 Dec 28. Antimicrob Agents Chemother. 2010. PMID: 20038627 Free PMC article.
-
Therapeutic approaches to Chlamydia infections.Expert Opin Pharmacother. 2005 Oct;6(13):2281-90. doi: 10.1517/14656566.6.13.2281. Expert Opin Pharmacother. 2005. PMID: 16218888 Review.
-
[Choice of antimicrobial drug for infections caused by Chlamydia trachomatis and Chlamydophila pneumoniae].Acta Med Croatica. 2004;58(4):329-33. Acta Med Croatica. 2004. PMID: 15700690 Review. Croatian.
Cited by
-
The efficacy and safety of nemonoxacin compared with levofloxacin in the treatment of community-acquired pneumonia: a systemic review and meta-analysis of randomized controlled trials.Infect Drug Resist. 2019 Feb 14;12:433-438. doi: 10.2147/IDR.S193233. eCollection 2019. Infect Drug Resist. 2019. PMID: 30863126 Free PMC article.
-
An Atypical Pneumonia Case of Quinolone-Refractory Chlamydia Pneumoniae Successfully Treated With Omadacycline.Infect Drug Resist. 2025 May 7;18:2357-2363. doi: 10.2147/IDR.S522259. eCollection 2025. Infect Drug Resist. 2025. PMID: 40357417 Free PMC article.
-
Nemonoxacin: first global approval.Drugs. 2014 Aug;74(12):1445-53. doi: 10.1007/s40265-014-0270-0. Drugs. 2014. PMID: 25079302 Review.
-
Amphipathic β2,2-Amino Acid Derivatives Suppress Infectivity and Disrupt the Intracellular Replication Cycle of Chlamydia pneumoniae.PLoS One. 2016 Jun 9;11(6):e0157306. doi: 10.1371/journal.pone.0157306. eCollection 2016. PLoS One. 2016. PMID: 27280777 Free PMC article.
-
Atypical Pneumonia: Updates on Legionella, Chlamydophila, and Mycoplasma Pneumonia.Clin Chest Med. 2017 Mar;38(1):45-58. doi: 10.1016/j.ccm.2016.11.011. Epub 2016 Dec 24. Clin Chest Med. 2017. PMID: 28159161 Free PMC article. Review.
References
-
- Centers for Disease Control and Prevention 2012. Sexually transmitted disease surveillance 2011 Division of STD Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, US Department of Health and Human Services, Atlanta, GA: http://www.cdc.gov/std/stats11/default.htm
-
- Hammerschlag MR, Kohlhoff SA, Apfalter PM. 2010. Chlamydia (Chlamydophila) pneumoniae, p 2467–2475 In Mandell GL, Bennett JE, Dolin R. (ed), Mandell, Douglas and Bennett's principles and practice of infectious diseases, 7th ed, vol 1 Elsevier, Philadelphia, PA
-
- Hooper DC, Strahilevitz J. 2010. Quinolones: anti-infective therapy, p 487–490 In Mandell GL, Bennett JE, Dolin R. (ed), Mandell, Douglas and Bennett's principles and practice of infectious diseases, 7th ed, vol 1 Elsevier, Philadelphia, PA
-
- Kings CR, Lin L, Leunk R. 2008. In vitro resistance development to nemonoxacin for Streptococcus pneumoniae, abstr C1-1971, p 131–132. Abstr. 48th Annu. Intersci. Conf. Antimicrob. Agents. Chemother. (ICAAC)-Infect. Dis. Soc. Am. (IDSA) 46th Annu Meet American Society for Microbiology and Infectious Diseases Society of America, Washington, DC
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical